Literature DB >> 23497796

Long-term alterations in maternal plasma proteome after sFlt1-induced preeclampsia in mice.

Egle Bytautiene1, Nataliya Bulayeva, Geeta Bhat, Li Li, Kevin P Rosenblatt, George R Saade.   

Abstract

OBJECTIVE: Preeclampsia is associated with long-term adverse maternal health, such as cardiovascular and metabolic diseases. The objective of this study was to determine whether preeclampsia in a well-characterized animal model that was induced by overexpression of soluble fms-like tyrosine kinase-1 (sFlt1) results in alterations in the maternal circulating proteome that persist long after delivery. STUDY
DESIGN: CD-1 mice at day 8 of gestation were injected with adenovirus that carried sFlt1 or the murine immunoglobulin G2α Fc fragment as control. Depleted maternal plasma was analyzed 6 months after delivery by label-free liquid chromatography-mass spectrometry assay. The tandem mass spectrometry data were searched against a mouse database, and the resultant intensity data were used to compare abundance of proteins across disease/control plasma pool. Results were analyzed with ingenuity pathways analysis. Right-tailed Fisher exact test was used to calculate a probability value.
RESULTS: Of 150 proteins that are common for both groups, ingenuity pathways analysis determined 105 proteins that were ready for analysis. Diseases and disorders analysis showed significant enrichment of proteins that are associated with cardiovascular disease. Within this cluster, the most abundant proteins were associated with vascular disease, atherosclerosis, and atherosclerotic lesions. Other top disease clusters were inflammatory response, organismal injury and abnormalities, and hematologic and metabolic disease.
CONCLUSION: Exposure to sFlt1-induced preeclampsia alters multiple biologic functions in mothers that persist later in life. Our results suggest that some of the long-term adverse outcomes that are associated with preeclampsia actually may be a consequence rather than a mere unmasking of an underlying predisposition. If similar results are found in humans, the development of preventive strategies for preeclampsia should also improve long-term maternal health.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23497796      PMCID: PMC3637875          DOI: 10.1016/j.ajog.2013.01.042

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  24 in total

1.  First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia.

Authors:  Ravi Thadhani; Walter P Mutter; Myles Wolf; Richard J Levine; Robert N Taylor; Vikas P Sukhatme; Jeffrey Ecker; S Ananth Karumanchi
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

2.  Phenotypic and metabolic characteristics of monocytes and granulocytes in preeclampsia.

Authors:  M T Gervasi; T Chaiworapongsa; P Pacora; N Naccasha; B H Yoon; E Maymon; R Romero
Journal:  Am J Obstet Gynecol       Date:  2001-10       Impact factor: 8.661

Review 3.  Preeclampsia: an excessive maternal inflammatory response to pregnancy.

Authors:  C W Redman; G P Sacks; I L Sargent
Journal:  Am J Obstet Gynecol       Date:  1999-02       Impact factor: 8.661

4.  Rats transgenic for human renin and human angiotensinogen as a model for gestational hypertension.

Authors:  Jürgen Bohlender; Detlev Ganten; Friedrich C Luft
Journal:  J Am Soc Nephrol       Date:  2000-11       Impact factor: 10.121

5.  Cardiovascular risk factors in women 10 years post early preeclampsia: the Preeclampsia Risk EValuation in FEMales study (PREVFEM).

Authors:  José T Drost; Ganiye Arpaci; Jan Paul Ottervanger; Menko Jan de Boer; Jim van Eyck; Yvonne T van der Schouw; Angela H E M Maas
Journal:  Eur J Prev Cardiol       Date:  2011-08-22       Impact factor: 7.804

6.  Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop.

Authors:  Gareth C McKeeman; Joy E S Ardill; Carolyn M Caldwell; Alyson J Hunter; Neil McClure
Journal:  Am J Obstet Gynecol       Date:  2004-10       Impact factor: 8.661

7.  Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.

Authors:  Sharon E Maynard; Jiang-Yong Min; Jaime Merchan; Kee-Hak Lim; Jianyi Li; Susanta Mondal; Towia A Libermann; James P Morgan; Frank W Sellke; Isaac E Stillman; Franklin H Epstein; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  J Clin Invest       Date:  2003-03       Impact factor: 14.808

8.  Circulating angiogenic factors and the risk of preeclampsia.

Authors:  Richard J Levine; Sharon E Maynard; Cong Qian; Kee-Hak Lim; Lucinda J England; Kai F Yu; Enrique F Schisterman; Ravi Thadhani; Benjamin P Sachs; Franklin H Epstein; Baha M Sibai; Vikas P Sukhatme; S Ananth Karumanchi
Journal:  N Engl J Med       Date:  2004-02-05       Impact factor: 91.245

9.  Enhanced thrombin generation in normal and hypertensive pregnancy.

Authors:  K de Boer; J W ten Cate; A Sturk; J J Borm; P E Treffers
Journal:  Am J Obstet Gynecol       Date:  1989-01       Impact factor: 8.661

Review 10.  Recent Insights into the pathogenesis of pre-eclampsia.

Authors:  J M Roberts; K Y Lain
Journal:  Placenta       Date:  2002-05       Impact factor: 3.481

View more
  11 in total

Review 1.  Genetic predisposition to preeclampsia is conferred by fetal DNA variants near FLT1, a gene involved in the regulation of angiogenesis.

Authors:  Kathryn J Gray; Richa Saxena; S Ananth Karumanchi
Journal:  Am J Obstet Gynecol       Date:  2017-11-11       Impact factor: 8.661

Review 2.  How does preeclampsia predispose to future cardiovascular disease?

Authors:  Dawn C Scantlebury; Sharonne N Hayes
Journal:  Curr Hypertens Rep       Date:  2014-09       Impact factor: 5.369

Review 3.  National Heart, Lung, and Blood Institute Working Group Report on Salt in Human Health and Sickness: Building on the Current Scientific Evidence.

Authors:  Young S Oh; Lawrence J Appel; Zorina S Galis; David A Hafler; Jiang He; Amanda L Hernandez; Bina Joe; S Ananth Karumanchi; Christine Maric-Bilkan; David Mattson; Nehal N Mehta; Gwendolyn Randolph; Michael Ryan; Kathryn Sandberg; Jens Titze; Eser Tolunay; Glenn M Toney; David G Harrison
Journal:  Hypertension       Date:  2016-06-20       Impact factor: 10.190

Review 4.  Abnormal Placentation Associated with Infertility as a Marker of Overall Health.

Authors:  Lauren W Sundheimer; Margareta D Pisarska
Journal:  Semin Reprod Med       Date:  2017-06-28       Impact factor: 1.303

5.  Exposure to placental ischemia impairs postpartum maternal renal and cardiac function in rats.

Authors:  Nina D Paauw; Jaap A Joles; Frank T Spradley; Bhavisha Bakrania; Zsuzsanna K Zsengeller; Arie Franx; Marianne C Verhaar; Joey P Granger; A Titia Lely
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2017-02-15       Impact factor: 3.619

Review 6.  Animal Models of Cardiovascular Complications of Pregnancy.

Authors:  Zolt Arany; Denise Hilfiker-Kleiner; S Ananth Karumanchi
Journal:  Circ Res       Date:  2022-06-09       Impact factor: 23.213

Review 7.  Pre-eclampsia and cardiovascular disease.

Authors:  Christina W Chen; Iris Z Jaffe; S Ananth Karumanchi
Journal:  Cardiovasc Res       Date:  2014-02-13       Impact factor: 10.787

8.  Exposure to experimental preeclampsia in mice enhances the vascular response to future injury.

Authors:  Dafina Pruthi; Eliyahu V Khankin; Robert M Blanton; Mark Aronovitz; Suzanne D Burke; Amy McCurley; S Ananth Karumanchi; Iris Z Jaffe
Journal:  Hypertension       Date:  2015-02-23       Impact factor: 10.190

Review 9.  Sex differences in cardiovascular disease - Impact on care and outcomes.

Authors:  K H Humphries; M Izadnegahdar; T Sedlak; J Saw; N Johnston; K Schenck-Gustafsson; R U Shah; V Regitz-Zagrosek; J Grewal; V Vaccarino; J Wei; C N Bairey Merz
Journal:  Front Neuroendocrinol       Date:  2017-04-18       Impact factor: 8.333

10.  In vivo experiments reveal the good, the bad and the ugly faces of sFlt-1 in pregnancy.

Authors:  Gabor Szalai; Yi Xu; Roberto Romero; Tinnakorn Chaiworapongsa; Zhonghui Xu; Po Jen Chiang; Hyunyoung Ahn; Birgitta Sundell; Olesya Plazyo; Yang Jiang; Mary Olive; Bing Wang; Suzanne M Jacques; Faisal Qureshi; Adi L Tarca; Offer Erez; Zhong Dong; Zoltan Papp; Sonia S Hassan; Edgar Hernandez-Andrade; Nandor Gabor Than
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.